Home › Gallbladder Cancer › Kentucky › Louisville
Gallbladder Cancer clinical trials in Louisville, KY
3 studies for Gallbladder Cancer are looking for participants at sites in and around Louisville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
RecruitingPhase 3
- Norton Cancer Institute (Site 115), Louisville
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RecruitingPhase 3
- Research Site, Louisville
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
RecruitingPhase 3
- Norton Cancer Institute - Audubon, Louisville
About Gallbladder Cancer
Gallbladder cancer is difficult to diagnose because there are no symptoms in its early stages. Read about tests, treatment options and prognosis.
More about Gallbladder Cancer on MedlinePlus
Gallbladder Cancer trials in other cities
- Nashville, TN4 studies
- New York City, NY4 studies
- Baldwin Park, CA4 studies
- Cleveland, OH4 studies
- Birmingham, AL3 studies
- Philadelphia, PA3 studies
- Dallas, TX3 studies
- Portland, OR3 studies
- Los Angeles, CA3 studies
- Oklahoma City, OK3 studies
- Seattle, WA3 studies
- Houston, TX3 studies
Other studies in Louisville
- Non-Small Cell Lung Cancer22 studies
- Obesity17 studies
- Overweight15 studies
- Cancer (all types)14 studies
- Heart Failure13 studies
- Acute Myeloid Leukemia12 studies
- Multiple Myeloma12 studies
- Ovarian Cancer12 studies
- Breast Cancer11 studies
- Head and Neck Squamous Cell Carcinoma11 studies
- Lung Cancer11 studies
- Melanoma10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.